Skip to main content
SpringerLink
Log in

Toxine botulinique et douleurs neuropathiques

Botulinum Toxin and Neuropathic Pain

  • Mise Au Point / Update
  • Published:
Douleur et Analgésie

Résumé

La toxine botulique de type A est une neurotoxine puissante, largement utilisée pour le traitement des hyperactivités musculaires telles que la dystonie et la spasticité. Plusieurs études cliniques récentes ont indiqué son intérêt par voie sous-cutanée ou intradermique dans les douleurs neuropathiques et la névralgie faciale essentielle. Cette revue fait le point sur l’efficacité, la sécurité d’emploi et les mécanismes potentiels d’action de la toxine botulinique de type A dans les douleurs neuropathiques périphériques ou centrales, ainsi que dans la névralgie faciale essentielle.

Abstract

Botulinum toxin type A is a potent neurotoxin which is widely used in the treatment of conditions involving muscular hyperactivity, such as dystonia and spasticity. Several recent clinical trials have indicated its beneficial impact, given subcutaneously or intradermally, on neuropathic pain and essential facial neuralgia. This review highlights the efficacy, safety of use and the potential mechanisms of action of botulinum toxin type A in peripheral or central neuropathic pain, and in essential facial neuralgia

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Références

  1. Ward AB, Molenaers G, Colosimo C, Berardelli A (2006) Clinical value of botulinum toxin in neurological indications. Eur J Neurol. 13:20–6

    Article  PubMed  Google Scholar 

  2. Colosimo C, Tiple D, Berardelli A (2012) Efficacy and safety of long-term botulinum toxin treatment in craniocervical dystonia: a systematic review. Neurotox Res 22:265–73

    Article  CAS  PubMed  Google Scholar 

  3. Aoki KR (2005) Review of a proposed mechanism for the antinociceptive action of botulinum toxin type A. Neurotoxicology 26:785–93

    Article  CAS  PubMed  Google Scholar 

  4. Finnerup NB, Haroutounian S, Kamerman P, et al (2016) Neuropathic pain: an updated grading system for research and clinical practice. Pain 157:1599–606

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  5. Bouhassira D, Lanteri-Minet M, Attal N, et al (2008) Prevalence of chronic pain with neuropathic characteristics in the general population. Pain 136:380–7

    Article  PubMed  Google Scholar 

  6. Attal N, Lanteri-Minet M, Laurent B, et al (2011) The specific disease burden of neuropathic pain: results of a French nationwide survey. Pain 152:2836–43

    Article  PubMed  Google Scholar 

  7. Finnerup NB, Attal N, Haroutounian S, et al (2015) Pharmacotherapy for neuropathic pain in adults: systematic review, meta-analysis and NeuPSIG recommendations. Lancet Neurol 14:162–73

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  8. Ranoux D, Attal N, Morain F, et al (2008) Botulinum toxin type A induces direct analgesic effects in chronic neuropathic pain: a double blind placebo controlled study. Ann Neurol 64:274–83

    Article  PubMed  Google Scholar 

  9. Yuan RY, Sheu JJ, Yu JM, et al (2009) Botulinum toxin for diabetic neuropathic pain: a randomized double-blind crossover trial. Neurology 72:1473–78

    Article  CAS  PubMed  Google Scholar 

  10. Xiao L, Mackey S, Hui H, et al (2010) Subcutaneous injection of botulinum toxin A is beneficial in postherpetic neuralgia. Pain Med 11:1827–33

    Article  PubMed  Google Scholar 

  11. Apalla Z, Sotiriou E, Lallas A, et al (2013) Botulinum toxin A in postherpetic neuralgia: a parallel, randomized, double-blind, single-sose, placebo-controlled trial. Clin J Pain 29:857–64

    Article  PubMed  Google Scholar 

  12. Attal N, de Andrade DC, Adam F, et al (2016) Efficacy and safety of repeated injections of botulinum toxin a in peripheral neuropathic pain and predictors of treatment response: a randomised double blind placebo controlled study. Lancet Neurol 15:555–65

    Article  CAS  PubMed  Google Scholar 

  13. Han ZA, Song DH, Oh HM, Chung ME (2016) Botulinum toxin type A for neuropathic pain in patients with spinal cord injury. Ann Neurol 79:569–78

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  14. Wu CJ, Lian YJ, Zheng YK, et al (2012) Botulinum toxin type A for the treatment of trigeminal neuralgia: results from a randomized, double-blind, placebo-controlled trial. Cephalalgia 32:443–50

    Article  PubMed  Google Scholar 

  15. Zúñiga C, Piedimonte F, Díaz S, Micheli F (2013) Acute treatment of trigeminal neuralgia with onabotulinum toxin A. Clin Neuropharmacol 36:146–50

    Article  PubMed  Google Scholar 

  16. Zhang H, Lian Y, Ma Y, et al (2014) Two doses of botulinum toxin type A for the treatment of trigeminal neuralgia: observation of therapeutic effect from a randomized, double-blind, placebo-controlled trial. J Headache Pain 15:65

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  17. Bouhassira D, Attal N, Fermanian J, et al (2004) Development and validation of the neuropathic pain symptom inventory. Pain 108:248–57

    Article  PubMed  Google Scholar 

  18. Morra ME, Elgebaly A, Elmaraezy A, et al (2016) Therapeutic efficacy and safety of Botulinum Toxin A Therapy in Trigeminal Neuralgia: a systematic review and meta-analysis of randomized controlled trials. J Headache Pain 17:63

    Article  PubMed  PubMed Central  Google Scholar 

  19. Attal N, Bouhassira D, Baron R, et al (2011) Assessing symptom profiles in neuropathic pain clinical trials: can it improve outcome? Eur J Pain 15:441–3

    Article  PubMed  Google Scholar 

  20. Baron R, Maier C, Attal N, et al (2017) Peripheral neuropathic pain: a mechanism-related organizing principle based on sensory profiles. Pain 158:261–72

    Article  PubMed  Google Scholar 

  21. Demant DT, Lund K, Vollert J, et al (2014) The effect of oxcarbazepine in peripheral neuropathic pain depends on pain phenotype: a randomised, double-blind, placebo-controlled phenotypestratified study. Pain 155:2263–73

    Article  CAS  PubMed  Google Scholar 

  22. Luvisetto S, Marinelli S, Lucchetti F, Marchi F, et al (2006) Botulinum neurotoxins and formalin-induced pain: central vs peripheral effects in mice. Brain Res 1082:124–31

    Article  CAS  PubMed  Google Scholar 

  23. Ishikawa H, Mitsui Y, Yoshitomi T, et al (2000) Presynaptic effects of botulinum toxin type A on the neuronally evoked response of albino and pigmented rabbit iris sphincter and dilator muscles. Jpn J Ophthalmol 44:106–9

    Article  CAS  PubMed  Google Scholar 

  24. Purkiss J, Welch M, Doward S, Foster K (2000) Capsaïcinstimulated release of substance P from cultured dorsal root ganglion neurons: involvement of two distinct mechanisms. Biochem Pharmacol 59:1403–6

    Article  CAS  PubMed  Google Scholar 

  25. Meunier FA, Colasante C, Faille L, et al (1996) Upregulation of calcitonin gene related peptide at mouse motor nerve terminals poisoned with botulinum type-A toxin. Pflugers Arch 431:R 297–8

    Article  Google Scholar 

  26. Durham PL, Cady Rand R., Cady R (2004) Regulation of calcitonin gene-related peptide secretion from trigeminal nerve cells by botulinum toxin type A: implications for migraine therapy. Headache 44:35–42

    Article  PubMed  Google Scholar 

  27. Morenilla-Palao C, Planells-Cases R, Garcia-Sanz N, Ferrer-Montiel A (2004) Regulated exocytosis contributes to protein kinase C potentiation of vanilloid receptor activity. J Biol Chem 279:25665–72

    Article  CAS  PubMed  Google Scholar 

  28. Luvisetto S, Marinelli S, Cobianchi S, Pavone F (2007) Antiallodynic efficacy of botulinum neurotoxin A in a model of neuropathic pain. Neuroscience 145:1–4

    Article  CAS  PubMed  Google Scholar 

  29. Gazerani P, Staahl C, Drewes AM, Arendt-Nielsen L (2006) The effects of botulinum toxin type A on capsaicin-evoked pain, flare, and secondary hyperalgesia in an experimental human model of trigeminal sensitization. Pain 122:315–25

    Article  CAS  PubMed  Google Scholar 

  30. Gazerani P, Pedersen NS, Staahl C, et al (2009) Subcutaneous botulinum toxin type A reduces capsaicin-induced trigeminal pain and vasomotor reactions in human skin. Pain 141:60–9

    Article  CAS  PubMed  Google Scholar 

  31. Krämer HH, Angerer C, Erbguth F, et al (2003) Botulinum toxin A reduces neurogenic flare but has almost no effect on pain and hyperalgesia in human skin. J Neurol 250:188–93

    Article  PubMed  Google Scholar 

  32. Bach-Rojecky L, Salković-Petrisić M, Lacković Z (2010) Botulinum toxin type A reduces pain supersensitivity in experimental diabetic neuropathy: bilateral effect after unilateral injection. Eur J Pharmacol 633:10–4

    Article  CAS  PubMed  Google Scholar 

  33. Bach-Rojecky L, Relja M, Lackovic Z (2005) Botulinum toxin type A in experimental neuropathic pain. J Neural Transm 112:215–9

    Article  CAS  PubMed  Google Scholar 

  34. Marinelli S, Vacca V, Ricordy R, et al (2012) The analgesic effect on neuropathic pain of retrogradely transported botulinum neurotoxin A involves Schwann cells and astrocytes. PLoS One 7:e47977

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  35. Paterson K, Lolignier S, Wood JN, et al (2014) Botulinum toxin-A treatment reduces human mechanical pain sensitivity and mechanotransduction. Ann Neurol 75:591–6

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  36. Donnet A, Simon E, Cuny E, et al (2017) French guidelines for diagnosis and treatment of classical trigeminal neuralgia (French Headache Society and French Neurosurgical Society). Rev Neurol (Paris) 173:131–51

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Inserm U-987 et CETD, hôpital Ambroise-Paré, AP-HP, 9, avenue Charles-de-Gaulle, F-92100, Boulogne-Billancourt, France

    N. Attal

Authors
  1. N. Attal
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to N. Attal.

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Attal, N. Toxine botulinique et douleurs neuropathiques. Douleur analg 30, 185–191 (2017). https://doi.org/10.1007/s11724-017-0535-y

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11724-017-0535-y

Mots clés

Keywords

Search

Navigation